HomeCompareSHGDF vs ABBV

SHGDF vs ABBV: Dividend Comparison 2026

SHGDF yields 10000.00% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SHGDF wins by $55137509079256512.00M in total portfolio value
10 years
SHGDF
SHGDF
● Live price
10000.00%
Share price
$0.02
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$55137509079256512.00M
Annual income
$54,073,795,673,722,890,000,000.00
Full SHGDF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — SHGDF vs ABBV

📍 SHGDF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSHGDFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SHGDF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SHGDF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SHGDF
Annual income on $10K today (after 15% tax)
$850,000.00/yr
After 10yr DRIP, annual income (after tax)
$45,962,726,322,664,450,000,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, SHGDF beats the other by $45,962,726,322,664,450,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SHGDF + ABBV for your $10,000?

SHGDF: 50%ABBV: 50%
100% ABBV50/50100% SHGDF
Portfolio after 10yr
$27568754539628256.00M
Annual income
$27,036,897,836,861,443,000,000.00/yr
Blended yield
98.07%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

SHGDF
No analyst data
Altman Z
-83.6
Piotroski
2/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SHGDF buys
0
ABBV buys
0
No recent congressional trades found for SHGDF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSHGDFABBV
Forward yield10000.00%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$55137509079256512.00M$102.3K
Annual income after 10y$54,073,795,673,722,890,000,000.00$24,771.77
Total dividends collected$55066727460582336.00M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SHGDF vs ABBV ($10,000, DRIP)

YearSHGDF PortfolioSHGDF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$1,010,700$1,000,000.00$11,550$430.00+$999.1KSHGDF
2$95,539,393$94,457,943.93$13,472$627.96+$95.53MSHGDF
3$8,447,007,736$8,344,780,585.66$15,906$926.08+$8446.99MSHGDF
4$698,565,746,383$689,527,448,105.17$19,071$1,382.55+$698565.73MSHGDF
5$54,040,711,670,213$53,293,246,321,583.74$23,302$2,095.81+$54040711.65MSHGDF
6$3,910,851,616,519,516$3,853,028,055,032,387.00$29,150$3,237.93+$3910851616.49MSHGDF
7$264,781,167,546,477,440$260,596,556,316,801,570.00$37,536$5,121.41+$264781167546.44MSHGDF
8$16,772,556,223,821,672,000$16,489,240,374,546,942,000.00$50,079$8,338.38+$16772556223821.62MSHGDF
9$994,124,678,068,810,000,000$976,178,042,909,320,800,000.00$69,753$14,065.80+$994124678068809.88MSHGDF
10$55,137,509,079,256,515,000,000$54,073,795,673,722,890,000,000.00$102,337$24,771.77+$55137509079256512.00MSHGDF

SHGDF vs ABBV: Complete Analysis 2026

SHGDFStock

Star Diamond Corporation engages in the exploration, development, and production of diamonds in Canada. The company's principal mineral properties include the Star Kimberlite property and the Orion South Kimberlite property located in Fort à la Corne area of Saskatchewan, Canada. It also holds 50% interest in the Buffalo Hills project located in north central Alberta, Canada. The company was formerly known as Shore Gold Inc. and changed its name to Star Diamond Corporation in February 2018. Star Diamond Corporation was incorporated in 1985 and is headquartered in Saskatoon, Canada.

Full SHGDF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this SHGDF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SHGDF vs SCHDSHGDF vs JEPISHGDF vs OSHGDF vs KOSHGDF vs MAINSHGDF vs JNJSHGDF vs MRKSHGDF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.